Two Cases of Anaphylaxis to Tranexamic Acid Confirmed by Drug Provocation Test: What About Skin Tests?

El Hanache H1, Verduguer M2, Collin L3, Babin M1, Favrelie S4, Vidal Husser S5, Maissiat MH6, Hoppe A1, Morisset M1
1Allergy Unit, Angers University Hospital, Angers, France
2Regional Allergology Center, Poitiers University Hospital, Poitiers, France
3Department of Pharmacology-Toxicoology and Pharmacovigilance Unit, Angers University Hospital, Angers, France
4Department of Pharmacology and Pharmacovigilance Unit, Poitiers University Hospital, Poitiers, France
5Department of Anesthesia and Reanimation, Saint Léonard Clinic, Trélazé, France
6Department of Pharmacology and Pharmacovigilance Unit, Angers University Hospital, Angers, France


Key words: Tranexamic acid. Anaphylaxis. Allergy. Hypersensitivity. Anesthesia. Skin testing. Drug provocation test.

The antifibrinolytic agent tranexamic acid (TXA) is a derivative of the amino acid lysine that blocks the lysine-binding sites on plasminogen.

TXA is used to treat heavy bleeding, such as menometrorrhagia, postpartum hemorrhage, and hemophilia. It is also administered to reduce the risk of death in bleeding trauma and traumatic brain injury (CRASH-2 and CRASH-3 [1]) and to prevent excessive blood loss during surgery.

The first case of TXA-induced anaphylaxis was reported in 2004 [2]. Since then, few cases have been reported. Here, we present the results of the first positive drug provocation test (DPT) in TXA-induced anaphylaxis.

The first patient was a 15-year-old girl with a history of asthma and hay fever who was referred to the allergy department for anaphylaxis during knee ligament reconstruction.

Preoperative intravenous treatments included 2 g cefazolin and 1 g TXA (Exacyl) (first exposure). A few minutes later, she developed tachycardia (heart rate, 160 bpm) and bronchospasm with desaturation. These were treated using saline volume expansion, adrenaline aerosol, and methylprednisolone. Surgery was postponed. Tryptase was not measured.

Two months later, the reaction, skin prick tests (SPTs) and intradermal tests (IDTs) were performed according to guidelines [3]. SPTs with iodinated povidone, chlorhexidine, and latex were negative. STP, IDT, and DPT (1 g cumulative dose) with cefazolin were negative.

SPT with TXA (IV Exacyl) (Sanofi-Aventis France) 100 mg/mL (undiluted) was negative, as were IDTs with TXA (0.1, 1, 10 mg/mL). The IDT wheal increased from 3 mm to 5 mm and was surrounded by erythema (9 mm) 20 minutes later at 10 mg/mL.

After signature of the informed consent form, an oral DPT was performed to assess TXA (Exacyl oral solution, 1 g/10 mL), with gradually increasing doses every 20 minutes (1 mg, 10 mg, 100 mg, 500 mg, 1000 mg). The patient presented with rhinocconjunctivitis, retroauricular itching, abdominal wheals, and cough 20 minutes after the eliciting dose of 100 mg (cumulative dose, 111 mg). The reaction was treated with dexamethasone and salbutamol.

The second patient was a 56-year-old man who had undergone knee arthroscopy and was referred for anaphylaxis during total knee replacement. Anesthesia was induced with propofol, sufentanil, atracurium, and ketamine. Dexamethasone, 1 g TXA (Exacyl) and cefazolin were administered 20 minutes later. Within 20 minutes, the patient developed hypotension (57/35 mmHg), tachycardia (99 bpm), desaturation (90%), and erythema, which were treated with saline and colloid volume expanders, 150 µg IV noradrenaline, 100 µg IV adrenaline, and methylprednisolone. Surgery was postponed. The serum tryptase level had increased to 14.2 µg/L 90 minutes after onset of the reaction (baseline, 4.6 µg/L [normal, <13.5 µg/L]). The histamine level was 26.2 nmol/L during the reaction and 10.1 nmol/L (normal, <10 nmol/L) 90 minutes after the onset of symptoms.

Six months later, IDTs with propofol 1 mg/mL, sufentanil 0.5 µg/mL, atracurium 0.01 mg/mL, ketamine 1 mg/mL, dexamethasone 0.04 mg/mL, and cefazolin 2 mg/mL were negative. Determination of specific IgE to latex and quaternary ammonium ions was also negative with ImmunoCAP (<0.10 kU/L). The DPTs to cefazolin (cumulative dose, 1 g) and dexamethasone (cumulative dose, 4 mg) were negative.

SPT was performed with undiluted TXA and IDT with TXA (Exacyl, 10, 100 mg/mL). IDT with TXA 100 mg/mL was positive: the wheal increased from 4 to 10 mm and was surrounded by erythema (45 mm) after 20 minutes.

Intravenous DPT to TXA (Exacyl) was performed once the patient had signed the informed consent document. Six minutes after the 50 mg dose (cumulative dose, 57.2 mg), the patient developed tachycardia (104 bpm), cough, conjunctivitis, and erythema, which were treated with antihistamine and prednisolone.

Subsequent surgery was performed with propofol, sufentanil, atracurium, ketamine, and cefazolin. No adverse effects were recorded.

Both cases were reported to our regional pharmacovigilance centers.

TXA has been on the World Health Organization (WHO) Model List of Essential Medicines since the 2011 adult edition [4]. In addition to other drugs that affect coagulation, TXA is recommended owing to its efficiency in gynecology, hematology, and surgery. For the past 10 years, increasingly frequent adverse effects, including hypersensitivity, have been reported in VigiBase (http://www.vigibase.org), the WHO global database of individual case safety reports. This greater frequency may be associated with the recent recommendations to use TXA in the CRASH studies (CRASH-2 and CRASH-3 [1]). A large study carried out in 2016 in the UK showed that of the various drugs that affect coagulation, TXA was the most used drug (5.9% of all cases) in perioperative care [5].
Previously published reports of anaphylaxis to TXA have been based on the clinical history, skin tests, and in vitro tests (Table), although DPTs have never been performed in cases of anaphylaxis. Spanish guidelines recommend SPT with undiluted TXA and IDT with TXA 10 mg/mL as the nonirritant concentrations [6].

We initially performed IDTs with TXA up to 10 mg/mL in the first case and up to 100 mg/mL in the second case and performed DPTs owing to discrepancies in skin testing recommendations. Subsequently, in order to address this gap in the literature, we performed IDTs with several TXA concentrations in healthy controls. We started with TXA 100 mg/mL but rapidly stopped because results for all 6 of the healthy controls were positive. We then administered TXA 10 mg/mL but again stopped because of 2 positive results from 11. Finally, we tested TXA 2 mg/mL, and 14 of 14 results were negative. Despite data from previous studies [6,7], we showed that IDT with undiluted TXA should not be performed because of the concentration is irritant and the results of IDT with TXA 10 mg/mL should be interpreted carefully because of a risk of false positives. If TXA-induced anaphylaxis is suspected, we suggest performing SPT with undiluted TXA and IDT up to 2 mg/mL, followed, if negative, by a DPT.

Given the presence of similar chemical structures and potential common epitopes, other lysine derivatives such as aminocaproic acid should be avoided [8]. Etamsylate seems to be a safe alternative [7-9].

Our study draws attention to the growing risk of anaphylaxis resulting from more frequent use of TXA, especially for trauma patients and in cardiac and orthopedic surgery. Each case should be referred to an allergist to perform appropriate skin tests and DPT if needed.

Acknowledgments
We are grateful to Manon BOUYE and Thomas BRIGLY for their help in the preparation of the manuscript.

Table. Skin Testing and Biological Assessments of Immediate Hypersensitivity to TXA in Previously Published Reports

<table>
<thead>
<tr>
<th>Age</th>
<th>Procedure</th>
<th>Immediate-Type</th>
<th>Skin Test Results</th>
<th>In Vitro</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>Total hip</td>
<td>Flushing, cardiac arrest</td>
<td>SPT positive with 1 mg/mL IDT positive with 0.01 mg/mL</td>
<td>BHRA: negative</td>
<td>[8]</td>
</tr>
<tr>
<td></td>
<td>arthroplasty</td>
<td></td>
<td></td>
<td>TXA-specific</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total knee</td>
<td>Hypotension, tachycardia</td>
<td>SPT positive with 100 mg/mL IDT positive with 0.2 mg/mL SPT and IDT negative in 5 healthy controls with 100 mg/mL</td>
<td>IgE negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>replacement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>Coronary artery</td>
<td>Flushing, desaturation, hypotension, tachycardia</td>
<td>SPT positive with 100 mg/mL SPT negative in 10 healthy controls with 100 mg/mL</td>
<td>BHRA: negative</td>
<td>[2]</td>
</tr>
<tr>
<td></td>
<td>bypass</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Unknown</td>
<td>Unknown</td>
<td>SPT negative with 100 mg/mL IDT positive with 100 mg/mL IDT negative with 10 mg/mL</td>
<td>None</td>
<td>[9]</td>
</tr>
<tr>
<td>15</td>
<td>Posterior spinal</td>
<td>Hypotension, tachycardia</td>
<td>SPT positive with 100 mg/mL IDT positive with 10 mg/mL</td>
<td>None</td>
<td>[10]</td>
</tr>
<tr>
<td></td>
<td>fusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BHRA, serum basophil histamine release assay; IDT, intradermal test; SPT, skin prick test; TXA, tranexamic acid.

Funding
The authors declare that no funding was received for the present study.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab

Kurosawa M, Shimizu Y, Sutoh Y, Sutoh E

1Department of Allergy and Respiratory Medicine, Sutoh Hospital, Annaka, Gunma, Japan
2Division of Respiratory Medicine, Kaminakai Family Clinic, Takasaki, Gunma, Japan
3Department of Surgery, Sutoh Hospital, Annaka, Gunma, Japan


Key words: Anti-interleukin 5 therapy. Asthma Control Test. Blood eosinophil count. Eosinophilic asthma. FEV1.


Eosinophils play a pivotal role in the inflammatory processes of asthma and have been the target of new biologic treatments for eosinophilic asthma. Benralizumab is the monoclonal antibody that targets the \( \alpha \) chain of the interleukin 5 (IL-5) receptor, and mepolizumab is the anti-IL-5 monoclonal antibody. We present the case of a patient with eosinophilic asthma and unsustained response to benralizumab after 3 years of therapy with mepolizumab.

A 42-year-old woman who had never smoked visited the clinic because of increasing dyspnea on January 22, 2016. She was treated with pranlukast 450 mg/d and fluticasone/formoterol 125 µg/5 µg inhaler (2 puffs per day). Because of unstable respiratory symptoms, she was occasionally given systemic corticosteroids. On February 27, 2016, the patient was admitted to hospital by an experienced pulmonologist. We confirmed the diagnosis of asthma using the Global Initiative for Asthma guidelines [1]. Forced expiratory volume in 1 second (FEV\(_1\)) was 74.1% of predicted, with an increase of 14.1% in FEV\(_1\) after salbutamol 180 µg (inhaler). The patient was not allergic. The results of testing indicated a serum total IgE level of 94 IU/mL and negative results in specific IgE for common inhaled allergens including Dermatophagoides farinae and Dermatophagoides pteronyssinus. Her regimen was changed to budesonide/formoterol 160 µg/4.5 µg (8 puffs per day) and montelukast 10 mg/d. She stopped using systemic corticosteroids, and daily use of the inhaler was reduced to 6 puffs per day on April 15.

On June 10, the peripheral blood eosinophil count was 228/µL, and serum total IgE was 155 IU/mL. FEV\(_1\) (% predicted) was 75.00%, and the score on the Asthma Control Test (ACT) was 13. The patient agreed to receive the first dose of mepolizumab (100 mg) (Figure). She had no history of poor adherence or comorbidities. On July 9, her blood eosinophil count decreased to 26/µL, while FEV\(_1\) and the ACT score were 75.17% and 16. On November 26, the blood eosinophil count, FEV\(_1\), and the ACT score were 20/µL, 76.76%, and 25.


Manuscript received June 24, 2020; accepted for publication October 26, 2020.

Hassan El Hanache
Allergy unit
Angers University Hospital
4, rue Larrey
49 933 Angers Cedex 9, Angers, France
E-mail : hassan.elhanache@gmail.com